[Ref No. T10759]

Novelty Metallothionein Mechanism of Action

University of Tasmania researchers have developed a novel therapeutic composition based on Metallothionein (MT). MT is a naturally occurring protein well documented as being involved in endogenous multi-modal reparative processes associated with neurodegenerative and other indications. MT has an excellent toxicology profile. The University of Tasmania has protected therapeutic applications of MT.

Value Proposition 

Under a separate patent, the University of Tasmania has protected peptide analogues of MT. The patent protection applies across any therapeutic applications of MT, (the subject of this patent) providing a strong intellectual property position for the development of any derivatives or synthetic analogues of MT. The value proposition is access to a defensive patent position around a wide range therapeutic applications of Metallothionein.

Business Opportunity 

This technology is available for licensing opportunities to interested industry partners.

Stage Development

Proof of Concept 


Prof Adrian West, A/Prof Meng Chuah, Prof James Vickers, and Prof Roger Chung 


Australian Patent Application No. 2003233259 (Granted), United States Patent No. 8,691,765 (Granted), European Patent Application No. 03727024.6 (Pending) 

See Related Technology

Emtins (Ref No. T02321)


"New insight into the molecular pathways of metallothionein-mediated neuroprotection and regeneration". R. S. Chung, J. Hidalgo and A. K. West; Journal of Neurochemistry. Volume 104, Issue 1, pages 14–20, January 2008


Metallothionein, neuronal growth, Alzheimer's, Parkinson's, Motor Neuron Disease, head injury